What AstraZeneca could cost London’s stock market if it moves to US

Wait 5 sec.

What AstraZeneca could cost London’s stock market if it moves to US | The IndependentNotifications can be managed in browser preferences.Jump to contentIndependentIndependent Bulletin homepageSocial PartnerWe are 8 logo (opens in a new tab)AllNewsSportCultureLifestyleKarl MatchettWednesday 02 July 2025 12:38 BSTThe US is AstraZeneca's largest revenue source (AFP/Getty)AstraZeneca's CEO, Pascal Soriot, has reportedly held private discussions about moving the pharmaceutical firm's stock market listing from London to the US.The potential move is primarily driven by the CEO's long-standing frustrations with UK regulations, including restrictions on new medicines and pricing structures.Such a shift would represent a significant blow to the London Stock Exchange, as AstraZeneca is currently its largest listed company with a market capitalisation exceeding £161bn.The US is AstraZeneca's largest revenue source, contributing $21.8bn (£15.3bn) of its $54bn (£39bn) total revenue in 2024, highlighting the market's importance to its growth strategy.The company previously abandoned plans for a £450m vaccine hub near Liverpool, citing “timing” and a funding gap, amid ongoing discussions with the UK government regarding pharmaceutical industry support.In fullFears over £160bn blow to London’s stock market as AstraZeneca considers listing move to USThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in